Toralizumab (IDEC 131) was a humanized monoclonal antibody and an immunosuppressive drug.

Possible indications included treatment of antibody-mediated disorders (immune thrombocytopenic purpura, lupus nephritis, rheumatoid arthritis), T-cell-mediated diseases (multiple sclerosis, Crohn's disease, and transplantations such as solid organ transplantation, pancreatic islet cell transplantation, and corneal transplantation), and B-cell malignancies such as CLL/small lymphocytic lymphoma, follicular cell lymphoma grade I or II, marginal zone lymphoma, mantle cell lymphoma, MALT lymphoma, Waldenström's macroglobulinemia, monocytoid B-cell lymphoma; relapsed/refractory Hodgkin's disease).

[1] In Phase II clinical trials regarding multiple sclerosis and Crohn's disease, thromboembolisms occurred in at least three patients.

[2] The drug was developed by IDEC Pharmaceuticals Corporation.

You can help Wikipedia by expanding it.This antineoplastic or immunomodulatory drug article is a stub.